VANCOUVER, B.C., Feb. 14, 2023 /PRNewswire/ — The sleep apnea devices market size reached USD 7.00 Billion in 2021 and is expected to register a CAGR of 6.9% during the forecast period, according to latest analysis by Emergen Research. One key factor driving market revenue growth is favorable reimbursement policies. For instance, on 15 December 2022, ProSomnus, Inc., a leader in the development of precise oral appliance therapy (OAT) for the management of obstructive sleep apnea (OSA), declared that Medicare would now reimburse for their ProSomnus EVO [PH] Sleep and Snore Device. Medicare Part B covers the cost of sleep apnea treatment, including equipment and doctor visits. A CPAP machine that is deemed to be medically required is partially covered by Medicare as durable medical equipment.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary +…
